VEGF Inhibitors and Ophthalmic Diseases

Vascular endothelial growth factor (VEGF) has demonstrated to be central to the pathology of several ophthalmic diseases.¹ Anti-VEGF therapy has dramatically improved the prognosis of many of these common vision-threatening retinal diseases. Click here to review current treatments of these diseases, with an emphasis on anti-VEGF therapy. 

 

Click here to read the supplement.

Author

 

1. Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248-1264.

 

 

Vascular endothelial growth factor (VEGF) has demonstrated to be central to the pathology of several ophthalmic diseases.¹ Anti-VEGF therapy has dramatically improved the prognosis of many of these common vision-threatening retinal diseases. Click here to review current treatments of these diseases, with an emphasis on anti-VEGF therapy. 

 

Click here to read the supplement.

Author

 

1. Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248-1264.

 

 

Vascular endothelial growth factor (VEGF) has demonstrated to be central to the pathology of several ophthalmic diseases.¹ Anti-VEGF therapy has dramatically improved the prognosis of many of these common vision-threatening retinal diseases. Click here to review current treatments of these diseases, with an emphasis on anti-VEGF therapy. 

 

Click here to read the supplement.

Author

 

1. Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248-1264.